The randomized controlled trial of the efficacy of mecobalamin and lafutidine after goshajinkigan administered in breast cancer patients with chemotherapy-induced peripheral neuropathy

INTERVENTION: Lafutidine is administered orally at the dose of 10 mg twice daily for 8 weeks. Mecobalamin is administered orally at the dose of 500 microgram three times daily for 8 weeks. CONDITION: chemotherapy‐induced peripheral neuropathy PRIMARY OUTCOME: The level of improvement of peripheral neuropathy is evaluated by Visual Analogue Scale (VAS). SECONDARY OUTCOME: Safety INCLUSION CRITERIA: 1)Breast cancer patient with taxane‐induced peripheral neuropathy, which continued more than 1 month after chemotherapy with taxane (paclitaxel, nab‐paclitaxel, docetaxel). 2)with residual peripheral neuropathy in spite of goshajinkigan administered 3)with digestive symptom such as upper abdominal discomfort 4)written informed consent